NCT07669194Not yet recruiting
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Observational Real-World Study of Glofitamab Combined With Selinexor for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 22 Jun 2026
- Start date
- 10 Jun 2026
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07669194
What you commit to
- Study type: Observational
- Planned participants: 30
- From 10 Jun 2026 to the primary completion date, 30 Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors.
- Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.
- Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study.
Other illness
- Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.
- Active autoimmune diseases requiring systemic immunosuppressive therapy.
- Clinically significant, severe, or uncontrolled cardiovascular diseases.
- Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).
- Severe gastrointestinal conditions that may significantly affect the absorption of oral medications.
- Known severe allergic reactions to any of the study drugs or their excipients.
Other
- Pregnant or breastfeeding women.
Who the study is looking for
- Age 18 years and older at the time of informed consent.
- Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).
- Relapsed or refractory disease, having previously received at least two lines of systemic therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
- Presence of measurable disease.
- Adequate hematologic, hepatic, and renal function.
- Willingness to use effective contraception methods during the study and for a specified period after the last dose.
- Willing and able to provide written informed consent and comply with the study protocol.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.